| Autor: |
Brigitte C. Widemann, Jack F. Shern, John W. Glod, Paul S. Meltzer, Maria J. Merino, Frank M. Balis, Elizabeth Fox, Oxana Kapustina, Steven G. Waguespack, Maya Lodish, Seth M. Steinberg, Eva Dombi, Claudia Derse-Anthony, Haiyan Lei, Yuelin Zhu, Srivandana Akshintala, Ira L. Kraft |
| Rok vydání: |
2023 |
| Popis: |
Doubling time of calcitonin and CEA for patient #12 was suggestive of progressive disease. Patient #12 experienced best response 434 days after starting vandetanib, with stable lesions in the thyroid bed (showed on T2-weighted MRI of the neck, A) and the mediastinum (showed on CT of the chest, B). In August 2016, the sum of longest diameter (per RECIST) of target lesions was consistent with SD (C,D) (note that not all target lesions are shown). Biomarker response in the two years prior (E) showed CEA doubling time 1.2 years (F) and calcitonin doubling time 1.67 years (G). Patient #12 was confirmed to have PD via RECIST February 2017. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
